The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II/III study of naptumomab estafenatox plus IFN-α versus IFN-α in advanced renal cell carcinoma.
Robert E. Hawkins
No relevant relationships to disclose
Martin Eric Gore
No relevant relationships to disclose
Yaroslav Shparyk
Research Funding - Active Biotech
Vladimir Bondar
Research Funding - Active Biotech
Oleg Gladkov
Research Funding - Active Biotech
Tosho Ganev
Research Funding - Active Biotech
Mihai Harza
Research Funding - Active Biotech
Serhii Polenkov
Research Funding - Active Biotech
Igor Bondarenko
Research Funding - Active Biotech
Petr A Karlov
Research Funding - Active Biotech
Oleg Karyakin
Research Funding - Active Biotech
Rustem Khasanov
Research Funding - Active Biotech
Gunnar Eric Hedlund
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Goran Forsberg
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Orjan Nordle
Employment or Leadership Position - Active Biotech
Stock Ownership - Active Biotech
Tim Eisen
Consultant or Advisory Role - AVEO; Bayer; GlaxoSmithKline; Pfizer; Roche
Stock Ownership - AstraZeneca
Honoraria - AVEO; Bayer; GlaxoSmithKline; Pfizer; Roche
Research Funding - Bayer; GlaxoSmithKline; Pfizer